Human chorionic gonadotropin as a target for cancer vaccines.

  • Authors:
    • P L Triozzi
    • V C Stevens
  • View Affiliations

  • Published online on: Friday, January 1, 1999
  • Pages: 7-24
  • DOI: 10.3892/or.6.1.7

Abstract

Human chorionic gonadotropin (hCG) is expressed by common cancers and may play a role in cell transformation as well as angiogenic, metastatic, and immune escape phenomena that are central to cancer progression. Clinical trials with a vaccine targeting the carboxy-terminal peptide of -hCG have indicated that tolerance to this oncofetal antigen can be broken. Humoral responses that may modulate the biologic activity of tumor-associated hCG as well as cellular responses to hCG have been generated. Studies are in progress to further define the biologic significance of hCG in cancer and to develop a vaccine approach that will best target this expression.
Journal Cover

January 1999
Volume 6 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Triozzi, P., & Stevens, V. (1999). Human chorionic gonadotropin as a target for cancer vaccines.. Oncology Reports, 6(1), 7-24.
MLA
Triozzi, and V C Stevens. "Human chorionic gonadotropin as a target for cancer vaccines.." Oncology Reports Oncology Reports 6.1 (1999): 7-24.
Chicago
Triozzi, and V C Stevens. "Human chorionic gonadotropin as a target for cancer vaccines.." Oncology Reports Oncology Reports 6 no. 1 (1999): 7-24.